WO2007087056A3 - Peramivir derivative for oral administration - Google Patents

Peramivir derivative for oral administration Download PDF

Info

Publication number
WO2007087056A3
WO2007087056A3 PCT/US2006/049006 US2006049006W WO2007087056A3 WO 2007087056 A3 WO2007087056 A3 WO 2007087056A3 US 2006049006 W US2006049006 W US 2006049006W WO 2007087056 A3 WO2007087056 A3 WO 2007087056A3
Authority
WO
WIPO (PCT)
Prior art keywords
peramivir
derivative
oral administration
adducts
composition
Prior art date
Application number
PCT/US2006/049006
Other languages
French (fr)
Other versions
WO2007087056A2 (en
Inventor
Michael Hite
Eric Holmes
Original Assignee
Scolr Pharma Inc
Michael Hite
Eric Holmes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scolr Pharma Inc, Michael Hite, Eric Holmes filed Critical Scolr Pharma Inc
Publication of WO2007087056A2 publication Critical patent/WO2007087056A2/en
Publication of WO2007087056A3 publication Critical patent/WO2007087056A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/40—Two or more oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A peramivir composition having improved oral activity is described. The composition includes an adduct selected from the group consisting of: a) adducts of vicinal dicarbonyl compounds with peramivir or salts or esters thereof; b) adducts of amino acids with peramivir; and c) combinations of a) and b).
PCT/US2006/049006 2006-01-13 2006-12-21 Peramivir derivative for oral administration WO2007087056A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US75890706P 2006-01-13 2006-01-13
US60/758,907 2006-01-13
US76027906P 2006-01-19 2006-01-19
US60/760,279 2006-01-19

Publications (2)

Publication Number Publication Date
WO2007087056A2 WO2007087056A2 (en) 2007-08-02
WO2007087056A3 true WO2007087056A3 (en) 2007-11-29

Family

ID=38309706

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/049006 WO2007087056A2 (en) 2006-01-13 2006-12-21 Peramivir derivative for oral administration

Country Status (1)

Country Link
WO (1) WO2007087056A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101367750B (en) * 2007-08-14 2012-05-23 中国人民解放军军事医学科学院毒物药物研究所 (1S,2S,3S,4R)-3-[(1S)-1-acet-ammonia-2-ethyl-butyl]-4- guanidino-2-hydroxyl-cyclopentyl-1-carboxylic acid aqua compound and medical uses thereof
CA2704778C (en) * 2007-11-05 2014-04-29 Scolr Pharma, Inc. Formulations for enhanced bioavailability of orally administered polar agents
WO2009129305A2 (en) * 2008-04-15 2009-10-22 Tsrl, Inc. Prodrugs of neuraminidase inhibitors
CN112694421A (en) * 2020-12-28 2021-04-23 日照正济药业有限公司 Preparation method and application of peramivir related substance

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3929991A (en) * 1973-07-26 1975-12-30 Dow Chemical Co Polycationic interferon induces
US6562861B1 (en) * 1997-12-17 2003-05-13 Biocryst Pharmaceuticals, Inc. Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors
US6576786B2 (en) * 1999-06-28 2003-06-10 Biocryst Pharmaceuticals Inc. Process for preparing substituted cyclopentane derivatives and novel crystalline structures thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3929991A (en) * 1973-07-26 1975-12-30 Dow Chemical Co Polycationic interferon induces
US6562861B1 (en) * 1997-12-17 2003-05-13 Biocryst Pharmaceuticals, Inc. Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors
US6576786B2 (en) * 1999-06-28 2003-06-10 Biocryst Pharmaceuticals Inc. Process for preparing substituted cyclopentane derivatives and novel crystalline structures thereof

Also Published As

Publication number Publication date
WO2007087056A2 (en) 2007-08-02

Similar Documents

Publication Publication Date Title
WO2008019289A3 (en) Tetrazolyl macrocyclic hepatitis c serine protease inhibitors
WO2008044243A3 (en) Novel process for the preparation of statins and their pharmaceutically acceptable salts thereof
WO2008021733A3 (en) Tetrazolyl acyclic hepatitis c serine protease inhibitors
WO2008021956A3 (en) Acylaminoheteroaryl hepatitis c virus protease inhibitors
WO2008022006A3 (en) Arylalkoxyl hepatitis c virus protease inhibitors
WO2007143694A3 (en) Macrocyclic oximyl hepatitis c protease inhibitors
WO2008019266A3 (en) Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors
WO2008021960A3 (en) Triazolyl macrocyclic hepatitis c serine protease inhibitors
WO2008019303A3 (en) Pyridazinonyl macrocyclic hepatitis c serine protease inhibitors
WO2008021871A3 (en) Triazolyl acyclic hepatitis c serine protease inhibitors
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
NO20085064L (en) 4,5-diphenyl-pyrimidinyl-oxy or mercapto-substituted carboxylic acids, processes for their preparation and use thereof as medicaments
WO2007090882A3 (en) Pharmaceutical extended release compositions comprising pramipexole
WO2009076166A3 (en) Oximyl hcv serine protease inhibitors
WO2009053828A3 (en) P3 hydroxyamino macrocyclic hepatitis c serine protease inhibitors
WO2013006451A3 (en) Macrocyclic insulin-degrading enzyme (ide) inhibitors and uses thereof
UA105777C2 (en) Pharmaceutical composition of potent hcv inhibitor for oral administration
WO2007127158A3 (en) Modification of percutaneous absorption of topically active materials
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
WO2010030359A3 (en) Macrocyclic hepatitis c serine protease inhibitors
WO2008070733A3 (en) Macrocyclic hepatitis c serine protease inhibitors and uses therefor
WO2009076173A3 (en) Fluorinated tripeptide hcv serine protease inhibitors
WO2007099553A3 (en) 1,3-dioxane carboxylic acids
WO2005085236A3 (en) Caspase inhibitors and uses thereof
EP1582521A4 (en) Fused furan compound

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06848026

Country of ref document: EP

Kind code of ref document: A2